Published: Friday 1 December 2017
The UK Stroke Forum 2017 took place this week at the ACC in Liverpool.
This three-day event is the largest multidisciplinary stroke event in the UK, attracting over 1,400 delegates from across the stroke care pathway. The event showcases what's hot in the UK stroke community, including the latest research, and how stroke professionals can get involved in research.
Stroke research training sessions on day one
The morning and afternoon training sessions were run by the Stroke Association's research team and our funded lecturers. The sessions were aimed at health professionals who wanted to get involved in stroke research for the first time, as well as those who had already started in a research career. They combined presentations and expert mentoring by a team of facilitators.
Research talks on day two
Professor Tom Robinson (University of Leicester) gave an insightful talk about lowering blood pressure to reduce stroke risk. This included the current PROHIBIT-ICH study which looks at how home blood pressure monitoring can help people manage their blood pressure after an intracerebral haemorrhage (a bleeding type of stroke). Professor Robinson is also working on the Stroke Association funded STAY ENCHANTED trial, looking at intensive blood pressure lowering for thrombolysis.
Professor David Werring from University College London provided an excellent overview of the current state of mechanical thrombectomy evidence. This was followed by a more in-depth insight by Professor Keith Muir (University of Glasgow). Professor Muir previously led the Stroke Association funded PISTE trial, which showed thrombectomy was feasible to deliver in an NHS setting.
Research talks on day three
Stroke Association HRH the Princess Margaret Clinical Reader, Dr Chris Price gave an update on stroke diagnosis, and where new technologies may help in the future, including the SMARTchip technology which may help emergency staff.
Updates from stroke clinical trials included early results from the PRESERVE trial into intensive blood pressure lowering to help established small vessel disease of the brain. The early results are promising, as this suggests the treatment is safe in these patients. The study is co-funded by us and the British Heart Foundation (BHF).